Olema Pharmaceuticals, Inc. (OLMA)
| Market Cap | 1.27B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -162.45M |
| Shares Out | 87.16M |
| EPS (ttm) | -1.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 806,803 |
| Open | 15.26 |
| Previous Close | 15.29 |
| Day's Range | 14.59 - 15.27 |
| 52-Week Range | 3.89 - 36.26 |
| Beta | 2.18 |
| Analysts | Strong Buy |
| Price Target | 44.89 (+207.68%) |
| Earnings Date | May 8, 2026 |
About OLMA
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. The company’s lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in seco... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for OLMA stock is "Strong Buy." The 12-month stock price target is $44.89, which is an increase of 207.68% from the latest price.
News
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
SAN FRANCISCO, April 21, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developm...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, April 02, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developm...
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancer Advanced enrollme...
Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA
LOS ANGELES--(BUSINESS WIRE)--Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA.
Why Is Olema Pharmaceuticals Stock Dropping On Monday?
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) stock is trading lower on Monday, in reaction to data from Roche Holdings AG's (OTC: RHHBY) phase 3 persevERA Breast Cancer study of giredestrant combined wit...
Olema Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Palazestrant is advancing in pivotal trials for ER+/HER2- breast cancer, showing strong efficacy in both ESR1 mutant and wild type populations, with key readouts expected in fall and 2028. OP-3136, a selective KAT6 inhibitor, aims for improved tolerability and will present initial data in Q2.
Olema Pharmaceuticals Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Recent data validate the efficacy of SERD/CERAN therapies in ER-positive, HER2-negative breast cancer, with palazestrant showing strong combinability and exposure. Ongoing trials and a robust pipeline, including a KAT6 inhibitor, position the company for significant market impact.
Olema Pharmaceuticals Transcript: Citi’s 2026 Virtual Oncology Leadership Summit
The summit highlighted the differentiation of palazestrant as a complete estrogen receptor antagonist with strong PK and tolerability, targeting both ESR1 wild-type and mutant breast cancer. Key trials OPERA-01 and OPERA-02 are progressing, with pivotal data expected in fall 2024 and late-decade, respectively.
Olema Pharmaceuticals Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The company is advancing palazestrant in two phase 3 trials for ER-positive, HER2-negative breast cancer, with a U.S. launch planned and significant market potential. Strong clinical data, strategic partnerships, and a new commercial focus position it for growth.
Olema Oncology to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developm...
Olema Oncology Announces Departure of Chief Operating and Financial Officer
SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developm...
Olema Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
The conference highlighted a robust clinical pipeline targeting ER-positive, HER2-negative breast cancer, with key phase III readouts for palazestrant expected this year and a strong focus on differentiation through efficacy and combination strategies. Commercialization plans include a U.S. launch in 2027 and global partnerships.
Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developme...
Olema Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference
Palazestrant is advancing in two phase III trials, targeting both ESR1-mutant and wild-type breast cancer populations, with key data readouts expected next year. Recent positive industry results have renewed confidence in SERDs, and ongoing combination studies may further expand market potential.
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developm...
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Olema Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025
The discussion highlighted progress on pivotal trials for a complete estrogen receptor antagonist in breast cancer, with key readouts expected in 2026 and 2028. Recent positive competitor data and strong internal results in both ESR1 mutant and wild type populations support confidence in market potential and future growth.
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, developme...
Pharma Bro Martin Shkreli Shorts Olema Pharmaceuticals Stock
Shares of Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) soared Tuesday in reaction to Roche Holdings AG‘s (OTC: RHHBY) phase 3 results from the lidERA Breast Cancer study of giredestrant in early-stage b...
OLMA stock: could today's 197% surge be just the beginning?
Olema Pharmaceuticals' (NASDAQ: OLMA stock) soared 197% in pre-market trading on Tuesday morning, despite no company announcements from Olema itself. The dramatic spike sent shockwaves through the bio...
Cancer Focused Olema Pharmaceuticals Stock Soars 150% - Here's Why
Olema Pharmaceuticals Inc. (NASDAQ: OLMA) stock is trading higher on Tuesday, with a session volume of 45.12 million compared to the average volume of 1.171 million as per data from Benzinga Pro.
Olema Pharmaceuticals Transcript: UBS Global Healthcare Conference 2025
Significant progress was highlighted for two clinical programs targeting ER-positive, HER2-negative breast cancer, with palazestrant showing superior efficacy and safety in phase III trials and OP-3136 advancing in early-phase studies. Key pivotal readouts and potential product launches are expected between 2025 and 2027.
Olema Pharmaceuticals Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Palazestrant demonstrates strong efficacy in both ESR1 mutant and wild-type breast cancer, with pivotal trials OPERA-01 and OPERA-02 progressing and significant market potential if wild-type activity is confirmed. Strategic collaborations and a robust financial position support ongoing development.